Lindbrook Capital’s Ascendis Pharma ASND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | $44.3K | Sell |
284
-6
| -2% | -$935 | ﹤0.01% | 1059 |
|
|
2024
Q4 | $39.9K | Buy |
290
+1
| +0.3% | +$138 | ﹤0.01% | 914 |
|
|
2024
Q3 | $43.2K | Buy |
289
+1
| +0.3% | +$149 | ﹤0.01% | 895 |
|
|
2024
Q2 | $39.3K | Sell |
288
-1
| -0.3% | -$136 | ﹤0.01% | 901 |
|
|
2024
Q1 | $43.7K | Buy |
289
+1
| +0.3% | +$151 | ﹤0.01% | 826 |
|
|
2023
Q4 | $36.3K | Buy |
288
+5
| +2% | +$630 | ﹤0.01% | 886 |
|
|
2023
Q3 | $26.5K | Sell |
283
-14
| -5% | -$1.31K | ﹤0.01% | 928 |
|
|
2023
Q2 | $26.5K | Sell |
297
-157
| -35% | -$14K | ﹤0.01% | 954 |
|
|
2023
Q1 | $48.7K | Sell |
454
-80
| -15% | -$8.58K | 0.01% | 706 |
|
|
2022
Q4 | $65.2K | Buy |
534
+43
| +9% | +$5.25K | 0.01% | 600 |
|
|
2022
Q3 | $51K | Sell |
491
-22
| -4% | -$2.29K | 0.01% | 629 |
|
|
2022
Q2 | $48K | Buy |
513
+116
| +29% | +$10.9K | 0.01% | 669 |
|
|
2022
Q1 | $47K | Sell |
397
-1
| -0.3% | -$118 | 0.01% | 704 |
|
|
2021
Q4 | $54K | Sell |
398
-127
| -24% | -$17.2K | 0.01% | 686 |
|
|
2021
Q3 | $84K | Sell |
525
-12
| -2% | -$1.92K | 0.02% | 303 |
|
|
2021
Q2 | $71K | Buy |
537
+97
| +22% | +$12.8K | 0.02% | 366 |
|
|
2021
Q1 | $57K | Buy |
440
+28
| +7% | +$3.63K | 0.01% | 396 |
|
|
2020
Q4 | $69K | Buy |
412
+3
| +0.7% | +$502 | 0.02% | 314 |
|
|
2020
Q3 | $63K | Buy |
409
+99
| +32% | +$15.2K | 0.02% | 295 |
|
|
2020
Q2 | $46K | Sell |
310
-100
| -24% | -$14.8K | 0.01% | 370 |
|
|
2020
Q1 | $46K | Sell |
410
-542
| -57% | -$60.8K | 0.02% | 338 |
|
|
2019
Q4 | $132K | Buy |
952
+100
| +12% | +$13.9K | 0.05% | 204 |
|
|
2019
Q3 | $82K | Buy |
852
+387
| +83% | +$37.2K | 0.03% | 275 |
|
|
2019
Q2 | $53K | Sell |
465
-200
| -30% | -$22.8K | 0.02% | 399 |
|
|
2019
Q1 | $78K | Sell |
665
-200
| -23% | -$23.5K | 0.03% | 272 |
|
|
2018
Q4 | $54K | Buy |
+865
| New | +$54K | 0.03% | 315 |
|